论文部分内容阅读
目的观察二甲双胍治疗T2DM与亚临床甲状腺功能减退症(下称“亚临床甲减”)的关系。方法选取T2DM患者396例,根据是否使用二甲双胍分为二甲双胍组和非二甲双胍组,比较两组一般资料和亚临床甲减的发病率,并分析T2DM合并亚临床甲减可能的危险因素。结果二甲双胍组BMI[(24.97±3.05)vs(26.71±3.64)kg/m2]、胰岛素抵抗指数(HOMA-IR)[(0.479±0.419)vs(0.605±0.408)]、促甲状腺激素(TSH)[(2.03±1.57)vs(2.48±1.96)μIU/ml]及亚临床甲减的发生率[(4.76%(9/189)vs 10.63%(22/207)]均低于非二甲双胍组(P<0.05)。性别是T2DM合并亚临床甲减的危险因素,而使用二甲双胍是保护因素(OR=0.325,P=0.013)。结论使用二甲双胍是T2DM合并亚临床甲减的保护因素,其可降低TSH水平,并可能降低亚临床甲减的发生率。
Objective To observe the relationship between metformin treatment of T2DM and subclinical hypothyroidism (hereinafter referred to as “subclinical hypothyroidism”). Methods 396 T2DM patients were selected. According to whether metformin was divided into metformin group and non-metformin group, the incidence of subclinical hypothyroidism and general data of two groups were compared. The possible risk factors of T2DM with subclinical hypothyroidism were analyzed. Results BMI [(24.97 ± 3.05) vs (26.71 ± 3.64) kg / m2], HOMA-IR [(0.479 ± 0.419) vs (0.605 ± 0.408)], thyrotropin (TSH) (2.03 ± 1.57) vs (2.48 ± 1.96) μIU / ml and the incidence of subclinical hypothyroidism were significantly lower than those in the non-metformin group (4.76% (9/189 vs 10.63%, 22/207) (OR = 0.325, P = 0.013) .Conclusion Metformin is a protective factor of subclinical hypothyroidism associated with T2DM, which can reduce the level of TSH , And may reduce the incidence of subclinical hypothyroidism.